Clinical research demonstrates that FDA-regulated psychedelic therapies can produce rapid and lasting effects for treatment-resistant conditions. Over 60 clinical trials in the last decade have provided substantial data demonstrating a low potential for physical dependence when administered in structured, supervised environments.
Engage with federal legislative bodies and regulatory agencies to advocate for and advance APP policies. We serve as a dedicated scientific and policy resource for key decision-makers and the media to ensure informed federal oversight.
Develop and implement a comprehensive policy strategy that includes the use of existing regulatory pathways. Our focus is on streamlining FDA and DEA coordination to accelerate the review process and establish clear prescribing guidelines for healthcare settings.
Promote and educate on the safe and effective introduction of prescription psychedelics. By sharing substantial clinical data—including research showing a favorable safety profile and low potential for physical dependence—we aim to overcome stigma and highlight the life-saving potential of these therapies for veterans and all Americans.
Americans with significant mental health conditions.
The annual economic cost of untreated mental illness.
TRD has only two FDA-approved products.
GAD has not seen an approved medication since 2007.
A coalition of industry leaders dedicated to the development and accessibility of safe, effective, and FDA-approved prescription psychedelic medicines.
